The Oncology Institute (TOI) Q1 2026: Specialty Pharmacy Drives 78% Revenue Growth, Florida Market Turns Profitable
The Oncology Institute’s first quarter 2026 results showcase robust revenue growth fueled by specialty pharmacy expansion and value-based care contract maturation, particularly in Florida where profitability was achieved. Operational enhancements including a provider portal launch and AI-driven efficiencies position the company for sustainable margin improvement. Management reaffirmed full-year guidance while upgrading free cash flow expectations, signaling confidence in execution and scalable growth.
Summary
- Value-Based Care Validation: Florida market profitability confirms scalability of capitated contracts.
- Pharmacy-Led Growth: Specialty pharmacy revenue surged on volume gains and operational optimization.
- Technology Leverage: Provider portal and AI initiatives underpin margin expansion and clinical adherence.
Business Overview
The Oncology Institute (TOI) is a community oncology provider delivering specialized, value-based cancer care across five U.S. states. The company generates revenue primarily through patient services under capitated and fee-for-service models, complemented by a rapidly growing specialty pharmacy segment that supplies oncology medications. TOI’s business model emphasizes integrated care pathways and risk-sharing arrangements with payors, supported by a network of employed and affiliated clinics.
Performance Analysis
TOI reported consolidated revenue of $147.4 million in Q1 2026, a 41.2% increase year-over-year, driven primarily by a 78% surge in specialty pharmacy revenue to $87.5 million. This segment now accounts for nearly 60% of total revenue, reflecting its central role in the company’s growth strategy. Patient services revenue grew 11.3% to $59.1 million, with capitated revenue rising 54% to $26.9 million, signaling continued traction in value-based contracts. Fee-for-service revenue declined 10%, impacted by pricing pressures and conservative reserve practices.
Gross profit rose 35.2% to $23.3 million, though overall gross margin compressed slightly to 15.8% due to lower-margin delegated capitation contracts and a prior year rebate. Specialty pharmacy gross margin remained stable at 19.2%, highlighting effective drug pricing management and scale benefits. Operating expenses increased modestly but improved as a percentage of revenue, with SG&A falling from 24.3% to 19.1%, reflecting operational leverage. Adjusted EBITDA loss narrowed to $2.4 million from $5.1 million a year ago, evidencing progress toward profitability. Cash and equivalents stood at $30.3 million, with free cash flow guidance raised to a positive range of $5 million to $15 million for 2026, driven by supplier negotiations and scale efficiencies.
- Growth Drivers: Specialty pharmacy volume growth and expanding capitated lives in Florida.
- Margin Dynamics: Stable pharmacy margins offset by lower patient services margin on delegated contracts.
- Cost Discipline: SG&A leverage and AI-driven savings initiatives improving operating efficiency.
Overall, TOI’s financial performance reflects successful execution of its integrated oncology care model, with specialty pharmacy and value-based contracts as key levers. The Florida market profitability milestone validates the company’s risk-sharing approach and sets the stage for further expansion and margin improvement.
Executive Commentary
"The first quarter of 2026 was a strong start to the year for TOI, delivering 41% year over year revenue growth, driven in part by strong capitated revenue growth and a record performance in our pharmacy business. We made meaningful progress on several fronts, including in Florida, where we reached profitability, marking an important milestone that reflects the maturation of our capitated relationships in the state, which is a proof point of our model."
Dan Vernage, Chief Executive Officer
"Attachment rate has exceeded our expectations in the year. The workflow changes that we implemented last year are continuing to pay dividends. As you look at the rest of the year, you can expect some subtle improvement quarter over quarter as we continue to refine those workflows and as additional value-based lives come onto the platform."
Rob Carter, Chief Financial Officer
Strategic Positioning
1. Expansion of Delegated Capitation Model in Florida
TOI’s Florida operation now covers 25 counties with approximately 200,000 Medicare Advantage lives under delegated capitation contracts, expected to go live by July 1, 2026. This expansion is a critical validation of the company’s hybrid employed and network provider model, delivering profitability and achieving a medical loss ratio (MLR) around 85%, slightly better than target. The strategy emphasizes tight clinical control and pathway adherence to manage costs and outcomes.
2. Specialty Pharmacy as a Growth and Margin Engine
The specialty pharmacy segment’s 78% revenue growth is driven by a 103% increase in prescription fills and improved attachment rates, partly due to provider education and workflow optimization. The sustained gross margin stability despite pricing pressures from legislation like the Inflation Reduction Act demonstrates TOI’s procurement and formulary management capabilities. Pharmacy growth also supports value-based care economics by capturing both Part B and Part D prescriptions.
3. Technology-Enabled Clinical and Operational Efficiencies
TOI is preparing to launch a proprietary provider portal intended to enhance engagement across its network and improve adherence to clinical pathways, a key driver of MLR performance. The portal will also facilitate access to ancillary services, including pharmacy and clinical trials, potentially increasing revenue streams. Concurrently, AI initiatives targeting revenue cycle management, prior authorization, and patient call centers are on track to deliver $2 million in operating expense savings in 2026, with further efficiency opportunities anticipated.
4. Capital Allocation Focused on Sustainable Profitability
Management is prioritizing investments in technology and clinic expansion, including plans to open seven new clinics in Florida in 2026 to support growing capitated populations. Discussions to refinance the senior secured convertible note indicate proactive balance sheet management. The company’s raised free cash flow guidance reflects improved vendor terms and scale benefits, enhancing financial flexibility.
5. Clinical Model Validation through CMS Enhancing Oncology Model
TOI reported nearly $2 million in Medicare savings under the CMS Enhancing Oncology Model, an episodic total cost of care risk program. This performance highlights the effectiveness of TOI’s integrated care pathways and high-value cancer care program in reducing unnecessary costs while maintaining quality, reinforcing the company’s value proposition to payors and patients.
Key Considerations
TOI’s first quarter illustrates the interplay between growth, margin management, and operational scale in a complex value-based oncology care environment. Investors should weigh these factors carefully as the company scales its risk-bearing contracts and specialty pharmacy platform.
Key Considerations:
- Capitated Revenue Mix Shift: Increasing capitated revenue share improves predictability but introduces margin pressure from delegated contracts.
- Pharmacy Volume and Pricing Dynamics: Volume growth offsets lower average revenue per fill, sustaining gross margins amid regulatory changes.
- Provider Engagement Tools: The upcoming portal launch is a critical lever for enhancing pathway adherence and expanding ancillary revenue opportunities.
- AI Integration Potential: Current $2 million savings are conservative; AI could materially enhance cost structure over the medium term.
- Market Expansion Risks: Florida rollout success is pivotal; execution risks remain in scaling clinic footprint and provider network.
Risks
TOI faces risks including the uncertainty of capitated contract performance across expanded geographies, potential reimbursement pressures in fee-for-service channels, and regulatory changes impacting drug pricing and oncology care models. The complexity of integrating new technology tools and scaling operations may also challenge execution. Additionally, refinancing of debt and maintaining liquidity are critical to support growth initiatives.
Forward Outlook
For Q2 2026, TOI anticipates adjusted EBITDA between a loss of $1 million and a gain of $1 million, reflecting seasonal factors and continued ramp of Florida delegated lives. Full-year 2026 guidance remains unchanged:
- Revenue: $630 million to $650 million
- Gross Profit: $97 million to $107 million
- Adjusted EBITDA: $0 to $9 million
- Free Cash Flow: Raised to positive $5 million to $15 million
Management highlighted ongoing focus on operational execution, technology investments, and expansion of delegated capitation partnerships as drivers of sustainable profitability and growth.
Takeaways
TOI’s Q1 results demonstrate meaningful progress in scaling a value-based oncology platform that integrates clinical care and pharmacy services. The Florida market’s profitability milestone validates the capitated model and supports confidence in expanding risk contracts. Specialty pharmacy volume growth and margin stability underpin revenue expansion and cash flow improvement. Technology initiatives, including the provider portal and AI automation, represent significant levers for future margin enhancement. Investors should monitor execution on Florida expansion, pathway adherence improvements, and AI integration as key indicators of sustainable profitability.
- Model Validation: Florida’s positive MLR and profitability confirm the effectiveness of TOI’s hybrid employed-network risk-sharing approach.
- Pharmacy Growth Sustainability: Continued volume gains and optimized workflows are essential to maintaining margin amid regulatory headwinds.
- Technology as a Differentiator: Provider portal rollout and AI savings will be critical for operational efficiency and clinical quality adherence.
Conclusion
The Oncology Institute’s first quarter 2026 results highlight strategic execution on multiple fronts, with specialty pharmacy growth and Florida market profitability as standout achievements. The company’s integrated oncology care model, supported by technology and risk-based contracts, positions it well for sustainable growth and margin improvement. Maintaining disciplined execution and scaling technology-enabled efficiencies will be key to realizing full-year guidance and long-term shareholder value.
Industry Read-Through
TOI’s performance provides valuable insights into the evolving community oncology landscape where integrated care models combining clinical services and specialty pharmacy can drive both improved patient outcomes and financial sustainability. The successful expansion of delegated capitation contracts with favorable MLRs in Florida underscores the viability of risk-sharing arrangements in oncology, a trend other providers may seek to emulate. Additionally, TOI’s use of technology platforms to enhance provider engagement and AI to reduce operational costs reflects broader digital transformation imperatives in healthcare. Competitors and investors should watch for how these strategic levers impact profitability and care quality across the sector.